These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30538285)

  • 1. By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737.
    Tailler M; Lindqvist LM; Gibson L; Adams JM
    Cell Death Differ; 2019 Sep; 26(9):1766-1781. PubMed ID: 30538285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.
    Milani M; Byrne DP; Greaves G; Butterworth M; Cohen GM; Eyers PA; Varadarajan S
    Cell Death Dis; 2017 Jan; 8(1):e2552. PubMed ID: 28079887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies.
    Al-Zebeeby A; Vogler M; Milani M; Richards C; Alotibi A; Greaves G; Dyer MJS; Cohen GM; Varadarajan S
    Haematologica; 2019 May; 104(5):1016-1025. PubMed ID: 30467206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
    Surman DR; Xu Y; Lee MJ; Trepel J; Brown K; Ramineni M; Splawn TG; Diggs LP; Hodges HC; Davis JL; Lee HS; Burt BM; Ripley RT
    Mol Cancer Ther; 2021 Aug; 20(8):1469-1480. PubMed ID: 34088830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
    Carter BZ; Mak PY; Tao W; Ayoub E; Ostermann LB; Huang X; Loghavi S; Boettcher S; Nishida Y; Ruvolo V; Hughes PE; Morrow PK; Haferlach T; Kornblau S; Muftuoglu M; Andreeff M
    Blood Cancer J; 2023 Apr; 13(1):57. PubMed ID: 37088806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
    Jullien M; Gomez-Bougie P; Chiron D; Touzeau C
    Cells; 2020 Mar; 9(3):. PubMed ID: 32183335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl-1 is a potential therapeutic target in multiple types of cancer.
    Akgul C
    Cell Mol Life Sci; 2009 Apr; 66(8):1326-36. PubMed ID: 19099185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
    Diepstraten ST; Yuan Y; La Marca JE; Young S; Chang C; Whelan L; Ross AM; Fischer KC; Pomilio G; Morris R; Georgiou A; Litalien V; Brown FC; Roberts AW; Strasser A; Wei AH; Kelly GL
    Cancer Cell; 2024 May; 42(5):850-868.e9. PubMed ID: 38670091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics.
    Ming Z; Lim SY; Stewart A; Pedersen B; Shklovskaya E; Menzies AM; Carlino MS; Kefford RF; Lee JH; Scolyer RA; Long GV; Rizos H
    J Invest Dermatol; 2023 Jul; 143(7):1246-1256.e8. PubMed ID: 36736995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.
    Kelly GL; Grabow S; Glaser SP; Fitzsimmons L; Aubrey BJ; Okamoto T; Valente LJ; Robati M; Tai L; Fairlie WD; Lee EF; Lindstrom MS; Wiman KG; Huang DC; Bouillet P; Rowe M; Rickinson AB; Herold MJ; Strasser A
    Genes Dev; 2014 Jan; 28(1):58-70. PubMed ID: 24395247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting MCL-1 protein to treat cancer: opportunities and challenges.
    Tantawy SI; Timofeeva N; Sarkar A; Gandhi V
    Front Oncol; 2023; 13():1226289. PubMed ID: 37601693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-Bclx
    Bonnefond ML; Florent R; Lenoir S; Lambert B; Abeilard E; Giffard F; Louis MH; Elie N; Briand M; Vivien D; Poulain L; Gauduchon P; N'Diaye M
    Oncotarget; 2018 Sep; 9(74):33896-33911. PubMed ID: 30338034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate Conformational Dynamics Drive Binding Specificity in Anti-Apoptotic Proteins Mcl-1 and Bcl-2.
    Wolf E; Lento C; Pu J; Dickinson BC; Wilson DJ
    Biochemistry; 2023 Jun; 62(11):1619-1630. PubMed ID: 37192192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Manzano-Muñoz A; Alcon C; Menéndez P; Ramírez M; Seyfried F; Debatin KM; Meyer LH; Samitier J; Montero J
    Front Cell Dev Biol; 2021; 9():695225. PubMed ID: 34568318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BH3-only proteins: the thorny end of the ER stress response.
    Glab JA; Doerflinger M; Puthalakath H
    Cell Death Dis; 2017 Jun; 8(6):e2889. PubMed ID: 28640250
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.
    Taylor J; Yeomans AM; Packham G
    Explor Target Antitumor Ther; 2020 Feb; 1(1):3-25. PubMed ID: 32924027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
    Li Y; Zhou D; Xu S; Rao M; Zhang Z; Wu L; Zhang C; Lin N
    Cancer Biol Med; 2022 May; 19(7):1109-10. PubMed ID: 35532134
    [No Abstract]   [Full Text] [Related]  

  • 18. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
    Dobrovolsky D; Wang ES; Morrow S; Leahy C; Faust T; Nowak RP; Donovan KA; Yang G; Li Z; Fischer ES; Treon SP; Weinstock DM; Gray NS
    Blood; 2019 Feb; 133(9):952-961. PubMed ID: 30545835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic role of RNA-binding protein GNL2 in glioma: Promotion of tumor development through enhancing protein synthesis.
    Yang X; Li X
    Oncol Lett; 2024 Jul; 28(1):307. PubMed ID: 38779136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of Beclin1-dependent autophagy sensitizes PTC cells to ABT737-induced death.
    Hu N; Tian Y; Song Y; Zang L
    Genet Mol Biol; 2024; 47(1):e20220170. PubMed ID: 38488525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.